Resources
The Value of a Disease Management Program
Relevant Articles
Browse through available scholarly journals, published medical journals, and studies to learn more about the value of participating in a disease management program.
Effects of a Disease Management Program in Individuals with Alpha-1 Antitrypsin Deficiency
This study assesses the impact of AlphaNet's disease management program on exacerbations, healthcare resource utilization, and health-related quality of life for individuals with AATD.
Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US
This study aimed to identify comorbid associations with AATD among patients diagnosed with COPD in the United States.
Disease Management Network Resources
The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult
The purpose of this journal is to provide recommendations for AATD diagnostic testing and management of adults with AATD and associated medical conditions.
The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials
A1PI therapy reduced elastin degradation, including pulmonary elastin, in patients with AATD.
Comparing Patients with ZZ Versus SZ Alpha-1 Antitrypsin Deficiency: Findings from AlphaNet's Disease Management Program
The aim of this study was to examine differences in demographic, health, and behavioral characteristics in individuals with ZZ and SZ genotypes of AATD within AlphaNet's Disease Management and Prevention Program.
Home-Based Multicomponent Intervention Increases Exercise Activity and Improves Body Mass Index: Results of a 5-Year Randomized Trial Among Individuals with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
This study was designed to increase exercise activity and improve body mass index among individuals with AATD-associated lung disease.
Patient Reported Pulmonary Symptoms, Exacerbations, and Management in a Cohort of Patients with Alpha-1 Antitrypsin Deficiency
The purpose is to identify pulmonary exacerbations in patients with AATD as it is critical due to the association with disease progression and poor health-related quality of life.
Quality of Life and Mortality Outcomes for Augmentation Naïve and Augmented Patients with Severe Alpha-1 Antitrypsin Deficiency
While randomized trials of augmentation therapy have demonstrated biochemical efficacy and lung tissue preservation using computed tomography (CT) densitometry, these studies were not adequately powered to demonstrate effectiveness in well-accepted clinical endpoints such as quality of life (QOL) or survival.